References
- Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492-503; PMID:21029960; http://dx.doi.org/10.1016/j.immuni.2010.10.002
- Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19:1597-608; PMID:24309663; http://dx.doi.org/10.1038/nm.3409
- Yan L, Yang Y, Zhang W, Chen X. Advanced Materials and Nanotechnology for Drug Delivery. Adv Mater 2014; (Forthcoming); PMID:24449177; http://dx.doi.org/10.1002/adma.201305683
- Devadasu VR, Bhardwaj V, Kumar MN. Can controversial nanotechnology promise drug delivery? Chem Rev 2013; 113:1686-735; PMID:23276295; http://dx.doi.org/10.1021/cr300047q
- Mo R, Jiang T, Di J, Tai W, Gu Z. Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem Soc Rev 2014; 43:3595-629; PMID:24626293; http://dx.doi.org/10.1039/c3cs60436e
- Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010; 10:3223-30; PMID:20726522; http://dx.doi.org/10.1021/nl102184c
- Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 2013; 3:13; PMID:23532930; http://dx.doi.org/10.3389/fcimb.2013.00013
- Singh M, Chakrapani A, O’Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007; 6:797-808; PMID:17931159; http://dx.doi.org/10.1586/14760584.6.5.797
- Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature 2009; 462:449-60; PMID:19940915; http://dx.doi.org/10.1038/nature08604
- Li WA, Mooney DJ. Materials based tumor immunotherapy vaccines. Curr Opin Immunol 2013; 25:238-45; PMID:23337254; http://dx.doi.org/10.1016/j.coi.2012.12.008
- Smith DM, Simon JK, Baker JR Jr. Applications of nanotechnology for immunology. Nat Rev Immunol 2013; 13:592-605; PMID:23883969; http://dx.doi.org/10.1038/nri3488
- Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O’Neil CP, Lee LK, Swartz MA, Hubbell JA. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007; 25:1159-64; PMID:17873867; http://dx.doi.org/10.1038/nbt1332
- Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007; 2:469-78; PMID:18654343; http://dx.doi.org/10.1038/nnano.2007.223
- Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010; 9:1095-107; PMID:20822351; http://dx.doi.org/10.1586/erv.10.89
- Look M, Bandyopadhyay A, Blum JS, Fahmy TM. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev 2010; 62:378-93; PMID:19922750; http://dx.doi.org/10.1016/j.addr.2009.11.011
- Khalil NM, Carraro E, Cótica LF, Mainardes RM. Potential of polymeric nanoparticles in AIDS treatment and prevention. Expert Opin Drug Deliv 2011; 8:95-112; PMID:21143001; http://dx.doi.org/10.1517/17425247.2011.543673
- Badiee A, Heravi Shargh V, Khamesipour A, Jaafari MR. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. Vaccine 2013; 31:735-49; PMID:23219436; http://dx.doi.org/10.1016/j.vaccine.2012.11.068
- Mittal A, Raber AS, Lehr CM, Hansen S. Particle based vaccine formulations for transcutaneous immunization. Hum Vaccin Immunother 2013; 9:1950-5; PMID:23778884; http://dx.doi.org/10.4161/hv.25217
- Hu Y, Zheng H, Huang W, Zhang C. A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle. Hum Vaccin Immunother 2014; 10:64-72; PMID:24091786; http://dx.doi.org/10.4161/hv.26635
- Ge C, Du J, Zhao L, Wang L, Liu Y, Li D, Yang Y, Zhou R, Zhao Y, Chai Z, et al. Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proc Natl Acad Sci U S A 2011; 108:16968-73; PMID:21969544; http://dx.doi.org/10.1073/pnas.1105270108
- Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, De Gregorio E, O’Hagan DT, Baudner B, Seubert A. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013; 31:3363-9; PMID:23684834; http://dx.doi.org/10.1016/j.vaccine.2013.05.007
- Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev Vaccines 2009; 8:483-92; PMID:19348563; http://dx.doi.org/10.1586/erv.09.5
- Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, Willers J, Geldhof C, Prior JO, Kündig TM, et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol 2012; 42:3049-61; PMID:22806397; http://dx.doi.org/10.1002/eji.201142361
- Kaba SA, McCoy ME, Doll TA, Brando C, Guo Q, Dasgupta D, Yang Y, Mittelholzer C, Spaccapelo R, Crisanti A, et al. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS One 2012; 7:e48304; PMID:23144750; http://dx.doi.org/10.1371/journal.pone.0048304
- Lobocka M, Szybalski WT. Advances in Virus Research. Vol. 79. Research Advances in Rabies. Academic Press, 1st edition. Edited by Alan C. Jackson. 2012; Chapter 4:60.
- Landesman-Milo D, Peer D. Altering the immune response with lipid-based nanoparticles. J Control Release 2012; 161:600-8; PMID:22230342; http://dx.doi.org/10.1016/j.jconrel.2011.12.034
- Silva JM, Videira M, Gaspar R, Préat V, Florindo HF. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 2013; 168:179-99; PMID:23524187; http://dx.doi.org/10.1016/j.jconrel.2013.03.010
- Hamdy S, Haddadi A, Hung RW, Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 2011; 63:943-55; PMID:21679733; http://dx.doi.org/10.1016/j.addr.2011.05.021
- Cruz LJ, Rueda F, Cordobilla B, Simón L, Hosta L, Albericio F, Domingo JC. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. Mol Pharm 2011; 8:104-16; PMID:21121669; http://dx.doi.org/10.1021/mp100178k
- Unger WW, van Beelen AJ, Bruijns SC, Joshi M, Fehres CM, van Bloois L, Verstege MI, Ambrosini M, Kalay H, Nazmi K, et al. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. J Control Release 2012; 160:88-95; PMID:22366522; http://dx.doi.org/10.1016/j.jconrel.2012.02.007
- Joshi MD, Unger WW, van Beelen AJ, Bruijns SC, Litjens M, van Bloois L, Kalay H, van Kooyk Y, Storm G. DC-SIGN mediated antigen-targeting using glycan-modified liposomes: formulation considerations. Int J Pharm 2011; 416:426-32; PMID:21371544; http://dx.doi.org/10.1016/j.ijpharm.2011.02.055
- Arigita C, Bevaart L, Everse LA, Koning GA, Hennink WE, Crommelin DJ, van de Winkel JG, van Vugt MJ, Kersten GF, Jiskoot W. Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response. Infect Immun 2003; 71:5210-8; PMID:12933866; http://dx.doi.org/10.1128/IAI.71.9.5210-5218.2003
- Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck F, Tyler PC, Davies NM. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003; 21:883-90; PMID:12547598; http://dx.doi.org/10.1016/S0264-410X(02)00536-4
- Hamdy S, Haddadi A, Shayeganpour A, Samuel J, Lavasanifar A. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharm Res 2011; 28:2288-301; PMID:21560020; http://dx.doi.org/10.1007/s11095-011-0459-9
- Xu Z, Wang Y, Zhang L, Huang L. Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano 2014; 8:3636-45; PMID:24580381; http://dx.doi.org/10.1021/nn500216y
- Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, Torensma R, Figdor CG. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 2010; 144:118-26; PMID:20156497; http://dx.doi.org/10.1016/j.jconrel.2010.02.013
- Cruz LJ, Tacken PJ, Fokkink R, Figdor CG. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials 2011; 32:6791-803; PMID:21724247; http://dx.doi.org/10.1016/j.biomaterials.2011.04.082
- Cohen JL, Almutairi A, Cohen JA, Bernstein M, Brody SL, Schuster DP, Fréchet JM. Enhanced cell penetration of acid-degradable particles functionalized with cell-penetrating peptides. Bioconjug Chem 2008; 19:876-81; PMID:18318462; http://dx.doi.org/10.1021/bc700414j
- Krpetić Z, Saleemi S, Prior IA, Sée V, Qureshi R, Brust M. Negotiation of intracellular membrane barriers by TAT-modified gold nanoparticles. ACS Nano 2011; 5:5195-201; PMID:21609028; http://dx.doi.org/10.1021/nn201369k
- Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006; 312:1027-30; PMID:16709779; http://dx.doi.org/10.1126/science.1125559
- Xiao D, Jia HZ, Zhang J, Liu CW, Zhuo RX, Zhang XZ. A dual-responsive mesoporous silica nanoparticle for tumor-triggered targeting drug delivery. Small 2014; 10:591-8; PMID:24106109; http://dx.doi.org/10.1002/smll.201301926
- Wen H, Guo J, Chang B, Yang W. pH-responsive composite microspheres based on magnetic mesoporous silica nanoparticle for drug delivery. Eur J Pharm Biopharm 2013; 84:91-8; PMID:23207322; http://dx.doi.org/10.1016/j.ejpb.2012.11.019
- K C RB, Thapa B, Xu P, K CR. pH and redox dual responsive nanoparticle for nuclear targeted drug delivery. Mol Pharm 2012; 9:2719-29; PMID:22876763; http://dx.doi.org/10.1021/mp300274g
- Lunov O, Syrovets T, Loos C, Nienhaus GU, Mailänder V, Landfester K, Rouis M, Simmet T. Amino-functionalized polystyrene nanoparticles activate the NLRP3 inflammasome in human macrophages. ACS Nano 2011; 5:9648-57; PMID:22111911; http://dx.doi.org/10.1021/nn203596e
- Palomäki J, Välimäki E, Sund J, Vippola M, Clausen PA, Jensen KA, Savolainen K, Matikainen S, Alenius H. Long, needle-like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism. ACS Nano 2011; 5:6861-70; PMID:21800904; http://dx.doi.org/10.1021/nn200595c
- Yazdi AS, Guarda G, Riteau N, Drexler SK, Tardivel A, Couillin I, Tschopp J. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc Natl Acad Sci U S A 2010; 107:19449-54; PMID:20974980; http://dx.doi.org/10.1073/pnas.1008155107
- Mathieu C, Rioux G, Dumas MC, Leclerc D. Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae challenge. Nanomedicine 2013; 9:839-48; PMID:23499666; http://dx.doi.org/10.1016/j.nano.2013.02.009
- Santos DM, Carneiro MW, de Moura TR, Soto M, Luz NF, Prates DB, Irache JM, Brodskyn C, Barral A, Barral-Netto M, et al. PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of Leishmania. Nanomedicine 2013; 9:985-95; PMID:23603355; http://dx.doi.org/10.1016/j.nano.2013.04.003
- Hamad I, Al-Hanbali O, Hunter AC, Rutt KJ, Andresen TL, Moghimi SM. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010; 4:6629-38; PMID:21028845; http://dx.doi.org/10.1021/nn101990a
- Moghimi SM, Andersen AJ, Ahmadvand D, Wibroe PP, Andresen TL, Hunter AC. Material properties in complement activation. Adv Drug Deliv Rev 2011; 63:1000-7; PMID:21689701; http://dx.doi.org/10.1016/j.addr.2011.06.002
- Pham CT, Mitchell LM, Huang JL, Lubniewski CM, Schall OF, Killgore JK, Pan D, Wickline SA, Lanza GM, Hourcade DE. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem 2011; 286:123-30; PMID:21047788; http://dx.doi.org/10.1074/jbc.M110.180760
- Joshi MD, Unger WJ, Storm G, van Kooyk Y, Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release 2012; 161:25-37; PMID:22580109; http://dx.doi.org/10.1016/j.jconrel.2012.05.010
- Li N, Peng LH, Chen X, Zhang TY, Shao GF, Liang WQ, Gao JQ. Antigen-loaded nanocarriers enhance the migration of stimulated Langerhans cells to draining lymph nodes and induce effective transcutaneous immunization. Nanomedicine 2014; 10:215-23; PMID:23792655; http://dx.doi.org/10.1016/j.nano.2013.06.007
- Sloat BR, Sandoval MA, Hau AM, He Y, Cui Z. Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J Control Release 2010; 141:93-100; PMID:19729045; http://dx.doi.org/10.1016/j.jconrel.2009.08.023
- Wang YT, Lu XM, Zhu F, Huang P, Yu Y, Zeng L, Long ZY, Wu YM. The use of a gold nanoparticle-based adjuvant to improve the therapeutic efficacy of hNgR-Fc protein immunization in spinal cord-injured rats. Biomaterials 2011; 32:7988-98; PMID:21784510; http://dx.doi.org/10.1016/j.biomaterials.2011.07.009
- Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004; 21:387-422; PMID:15719481; http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v21.i5.20
- Clawson C, Huang CT, Futalan D, Seible DM, Saenz R, Larsson M, Ma W, Minev B, Zhang F, Ozkan M, et al. Delivery of a peptide via poly(D,L-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. Nanomedicine 2010; 6:651-61; PMID:20348031; http://dx.doi.org/10.1016/j.nano.2010.03.001
- Manish M, Rahi A, Kaur M, Bhatnagar R, Singh S. A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge. PLoS One 2013; 8:e61885; PMID:23637922; http://dx.doi.org/10.1371/journal.pone.0061885
- Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470:543-7; PMID:21350488; http://dx.doi.org/10.1038/nature09737
- Flemming A. Vaccines: nano-adjuvant: double TLR stimulation is the key. Nat Rev Drug Discov 2011; 10:258; PMID:21455232; http://dx.doi.org/10.1038/nrd3426
- Ge Y, Zhang Y, Xia J, Ma M, He S, Nie F, Gu N. Effect of surface charge and agglomerate degree of magnetic iron oxide nanoparticles on KB cellular uptake in vitro. Colloids Surf B Biointerfaces 2009; 73:294-301; PMID:19564099; http://dx.doi.org/10.1016/j.colsurfb.2009.05.031
- Qiu Y, Liu Y, Wang L, Xu L, Bai R, Ji Y, Wu X, Zhao Y, Li Y, Chen C. Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. Biomaterials 2010; 31:7606-19; PMID:20656344; http://dx.doi.org/10.1016/j.biomaterials.2010.06.051
- Xia T, Kovochich M, Liong M, Meng H, Kabehie S, George S, Zink JI, Nel AE. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 2009; 3:3273-86; PMID:19739605; http://dx.doi.org/10.1021/nn900918w
- Yue ZG, Wei W, Lv PP, Yue H, Wang LY, Su ZG, Ma GH. Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles. Biomacromolecules 2011; 12:2440-6; PMID:21657799; http://dx.doi.org/10.1021/bm101482r
- Wegmann F, Gartlan KH, Harandi AM, Brinckmann SA, Coccia M, Hillson WR, Kok WL, Cole S, Ho LP, Lambe T, et al. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol 2012; 30:883-8; PMID:22922673; http://dx.doi.org/10.1038/nbt.2344
- Luo Z, Li P, Deng J, Gao N, Zhang Y, Pan H, Liu L, Wang C, Cai L, Ma Y. Cationic polypeptide micelle-based antigen delivery system: a simple and robust adjuvant to improve vaccine efficacy. J Control Release 2013; 170:259-67; PMID:23742880; http://dx.doi.org/10.1016/j.jconrel.2013.05.027
- Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M, Reinhold B, Keskin DB, Reinherz EL, Sasada T. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 2011; 32:3666-78; PMID:21345488; http://dx.doi.org/10.1016/j.biomaterials.2011.01.067
- Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A 2012; 109:1080-5; PMID:22247289; http://dx.doi.org/10.1073/pnas.1112648109
- Caputo A, Castaldello A, Brocca-Cofano E, Voltan R, Bortolazzi F, Altavilla G, Sparnacci K, Laus M, Tondelli L, Gavioli R, et al. Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. Vaccine 2009; 27:3605-15; PMID:19464541; http://dx.doi.org/10.1016/j.vaccine.2009.03.047
- Cho NH, Cheong TC, Min JH, Wu JH, Lee SJ, Kim D, Yang JS, Kim S, Kim YK, Seong SY. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat Nanotechnol 2011; 6:675-82; PMID:21909083; http://dx.doi.org/10.1038/nnano.2011.149
- de Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, van der Vlies AJ, Swartz MA, Hubbell JA. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A 2013; 110:19902-7; PMID:24248387; http://dx.doi.org/10.1073/pnas.1313152110
- Katare YK, Panda AK, Lalwani K, Haque IU, Ali MM. Potentiation of immune response from polymer-entrapped antigen: toward development of single dose tetanus toxoid vaccine. Drug Deliv 2003; 10:231-8; PMID:14612338; http://dx.doi.org/10.1080/714044314
- Sen D, Deerinck TJ, Ellisman MH, Parker I, Cahalan MD. Quantum dots for tracking dendritic cells and priming an immune response in vitro and in vivo. PLoS One 2008; 3:e3290; PMID:18820727; http://dx.doi.org/10.1371/journal.pone.0003290
- Sheng KC, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Apostolopoulos V, Pietersz GA. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol 2008; 38:424-36; PMID:18200633; http://dx.doi.org/10.1002/eji.200737578
- Cambi A, Lidke DS, Arndt-Jovin DJ, Figdor CG, Jovin TM. Ligand-conjugated quantum dots monitor antigen uptake and processing by dendritic cells. Nano Lett 2007; 7:970-7; PMID:17388641; http://dx.doi.org/10.1021/nl0700503
- Badiee A, Davies N, McDonald K, Radford K, Michiue H, Hart D, Kato M. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine 2007; 25:4757-66; PMID:17512099; http://dx.doi.org/10.1016/j.vaccine.2007.04.029
- van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004; 64:4357-65; PMID:15205352; http://dx.doi.org/10.1158/0008-5472.CAN-04-0138
- Kwon YJ, James E, Shastri N, Fréchet JM. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci U S A 2005; 102:18264-8; PMID:16344458; http://dx.doi.org/10.1073/pnas.0509541102
- Chou LY, Ming K, Chan WC. Strategies for the intracellular delivery of nanoparticles. Chem Soc Rev 2011; 40:233-45; PMID:20886124; http://dx.doi.org/10.1039/c0cs00003e
- Won YW, Lim KS, Kim YH. Intracellular organelle-targeted non-viral gene delivery systems. J Control Release 2011; 152:99-109; PMID:21255626; http://dx.doi.org/10.1016/j.jconrel.2011.01.013
- Lee CH, Cheng SH, Huang IP, Souris JS, Yang CS, Mou CY, Lo LW. Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. Angew Chem Int Ed Engl 2010; 49:8214-9; PMID:20865709; http://dx.doi.org/10.1002/anie.201002639
- Hu Y, Litwin T, Nagaraja AR, Kwong B, Katz J, Watson N, Irvine DJ. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett 2007; 7:3056-64; PMID:17887715; http://dx.doi.org/10.1021/nl071542i
- Nair S, Zhou F, Reddy R, Huang L, Rouse BT. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med 1992; 175:609-12; PMID:1531064; http://dx.doi.org/10.1084/jem.175.2.609
- Flanary S, Hoffman AS, Stayton PS. Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug Chem 2009; 20:241-8; PMID:19125614; http://dx.doi.org/10.1021/bc800317a
- Yezhelyev MV, Qi L, O’Regan RM, Nie S, Gao X. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J Am Chem Soc 2008; 130:9006-12; PMID:18570415; http://dx.doi.org/10.1021/ja800086u
- Nakamura T, Moriguchi R, Kogure K, Shastri N, Harashima H. Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes. Mol Ther 2008; 16:1507-14; PMID:18560420; http://dx.doi.org/10.1038/mt.2008.122
- Lutsiak ME, Kwon GS, Samuel J. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol 2006; 58:739-47; PMID:16734975; http://dx.doi.org/10.1211/jpp.58.6.0004
- Shima F, Akagi T, Uto T, Akashi M. Manipulating the antigen-specific immune response by the hydrophobicity of amphiphilic poly(γ-glutamic acid) nanoparticles. Biomaterials 2013; 34:9709-16; PMID:24016848; http://dx.doi.org/10.1016/j.biomaterials.2013.08.064
- Ballester M, Nembrini C, Dhar N, de Titta A, de Piano C, Pasquier M, Simeoni E, van der Vlies AJ, McKinney JD, Hubbell JA, et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 2011; 29:6959-66; PMID:21787826; http://dx.doi.org/10.1016/j.vaccine.2011.07.039
- Heinze BC, Yoon JY. Nanoparticle immunoagglutination Rayleigh scatter assay to complement microparticle immunoagglutination Mie scatter assay in a microfluidic device. Colloids Surf B Biointerfaces 2011; 85:168-73; PMID:21411297; http://dx.doi.org/10.1016/j.colsurfb.2011.02.024
- Glenny APC, Waddington H, Falacce U. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926; 29:31-40; http://dx.doi.org/10.1002/path.1700290106
- Hem SL, Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007; 6:685-98; PMID:17931150; http://dx.doi.org/10.1586/14760584.6.5.685
- Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9:847-56; PMID:18604214; http://dx.doi.org/10.1038/ni.1631
- Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O’Hagan DT, Pétrilli V, Tschopp J, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009; 106:870-5; PMID:19139407; http://dx.doi.org/10.1073/pnas.0804897106
- Atianand MK, Rathinam VA, Fitzgerald KA. SnapShot: inflammasomes. Cell 2013; 153:272-e1, e1; PMID:23540703; http://dx.doi.org/10.1016/j.cell.2013.03.009
- Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140:821-32; PMID:20303873; http://dx.doi.org/10.1016/j.cell.2010.01.040
- Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008; 181:17-21; PMID:18566365; http://dx.doi.org/10.4049/jimmunol.181.1.17
- Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/nm.2028
- Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, Carter AB, Rothman PB, Flavell RA, Sutterwala FS. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A 2008; 105:9035-40; PMID:18577586; http://dx.doi.org/10.1073/pnas.0803933105
- Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320:674-7; PMID:18403674; http://dx.doi.org/10.1126/science.1156995
- Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-41; PMID:16407889; http://dx.doi.org/10.1038/nature04516
- Scharf B, Clement CC, Wu XX, Morozova K, Zanolini D, Follenzi A, Larocca JN, Levon K, Sutterwala FS, Rand J, et al. Annexin A2 binds to endosomes following organelle destabilization by particulate wear debris. Nat Commun 2012; 3:755; PMID:22453828; http://dx.doi.org/10.1038/ncomms1754
- Morishige T, Yoshioka Y, Tanabe A, Yao X, Tsunoda S, Tsutsumi Y, Mukai Y, Okada N, Nakagawa S. Titanium dioxide induces different levels of IL-1beta production dependent on its particle characteristics through caspase-1 activation mediated by reactive oxygen species and cathepsin B. Biochem Biophys Res Commun 2010; 392:160-5; PMID:20059972; http://dx.doi.org/10.1016/j.bbrc.2009.12.178
- Reisetter AC, Stebounova LV, Baltrusaitis J, Powers L, Gupta A, Grassian VH, Monick MM. Induction of inflammasome-dependent pyroptosis by carbon black nanoparticles. J Biol Chem 2011; 286:21844-52; PMID:21525001; http://dx.doi.org/10.1074/jbc.M111.238519
- Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science 2006; 311:622-7; PMID:16456071; http://dx.doi.org/10.1126/science.1114397
- Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11:136-40; PMID:20023662; http://dx.doi.org/10.1038/ni.1831
- Kool M, Pétrilli V, De Smedt T, Rolaz A, Hammad H, van Nimwegen M, Bergen IM, Castillo R, Lambrecht BN, Tschopp J. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008; 181:3755-9; PMID:18768827; http://dx.doi.org/10.4049/jimmunol.181.6.3755
- Franchi L, Núñez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008; 38:2085-9; PMID:18624356; http://dx.doi.org/10.1002/eji.200838549
- Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, Nemazee D. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006; 314:1936-8; PMID:17185603; http://dx.doi.org/10.1126/science.1135299
- Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996; 271:348-50; PMID:8553069; http://dx.doi.org/10.1126/science.271.5247.348
- Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 2010; 4:3623-32; PMID:20553005; http://dx.doi.org/10.1021/nn901372t
- Cedervall T, Lynch I, Lindman S, Berggård T, Thulin E, Nilsson H, Dawson KA, Linse S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A 2007; 104:2050-5; PMID:17267609; http://dx.doi.org/10.1073/pnas.0608582104
- Zhu M, Perrett S, Nie G. Understanding the particokinetics of engineered nanomaterials for safe and effective therapeutic applications. Small 2013; 9:1619-34; PMID:23225644; http://dx.doi.org/10.1002/smll.201201630
- Zhu M, Nie G, Meng H, Xia T, Nel A, Zhao Y. Physicochemical properties determine nanomaterial cellular uptake, transport, and fate. Acc Chem Res 2013; 46:622-31; PMID:22891796; http://dx.doi.org/10.1021/ar300031y
- Nel AE, Mädler L, Velegol D, Xia T, Hoek EM, Somasundaran P, Klaessig F, Castranova V, Thompson M. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009; 8:543-57; PMID:19525947; http://dx.doi.org/10.1038/nmat2442
- Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010; 8:62-73; PMID:19966816; http://dx.doi.org/10.1038/nrmicro2240
- Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 113:823-39; PMID:16002369; http://dx.doi.org/10.1289/ehp.7339
- Human respiratory tract model for radiological protection. A report of a Task Group of the International Commission on Radiological Protection. Ann ICRP 1994; 24:1-482; PMID:7726471
- Dose coefficients for intakes of radionuclides by workers. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. Ann ICRP 1994; 24:1-83; PMID:7668473
- Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008; 38:1404-13; PMID:18389478; http://dx.doi.org/10.1002/eji.200737984
- Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263:1600-3; PMID:8128245; http://dx.doi.org/10.1126/science.8128245
- Peppas NA. Intelligent therapeutics: biomimetic systems and nanotechnology in drug delivery. Adv Drug Deliv Rev 2004; 56:1529-31; PMID:15350286; http://dx.doi.org/10.1016/j.addr.2004.07.001
- Emerich DF, Thanos CG. Targeted nanoparticle-based drug delivery and diagnosis. J Drug Target 2007; 15:163-83; PMID:17454354; http://dx.doi.org/10.1080/10611860701231810
- Fakhari A, Baoum A, Siahaan TJ, Le KB, Berkland C. Controlling ligand surface density optimizes nanoparticle binding to ICAM-1. J Pharm Sci 2011; 100:1045-56; PMID:20922813; http://dx.doi.org/10.1002/jps.22342
- Wang H, Wu Y, Zhao R, Nie G. Engineering the assemblies of biomaterial nanocarriers for delivery of multiple theranostic agents with enhanced antitumor efficacy. Adv Mater 2013; 25:1616-22; PMID:23341059; http://dx.doi.org/10.1002/adma.201204750
- Gutierro I, Hernández RM, Igartua M, Gascón AR, Pedraz JL. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002; 21:67-77; PMID:12443664; http://dx.doi.org/10.1016/S0264-410X(02)00435-8
- Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007; 28:5344-57; PMID:17825905; http://dx.doi.org/10.1016/j.biomaterials.2007.08.015
- Li X, Sloat BR, Yanasarn N, Cui Z. Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design. Eur J Pharm Biopharm 2011; 78:107-16; PMID:21182941; http://dx.doi.org/10.1016/j.ejpb.2010.12.017
- Jung T, Kamm W, Breitenbach A, Hungerer KD, Hundt E, Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res 2001; 18:352-60; PMID:11442276; http://dx.doi.org/10.1023/A:1011063232257
- Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, McKenzie IF, Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004; 173:3148-54; PMID:15322175; http://dx.doi.org/10.4049/jimmunol.173.5.3148
- Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008; 3:145-50; PMID:18654486; http://dx.doi.org/10.1038/nnano.2008.30
- Keelan JA. Nanotoxicology: nanoparticles versus the placenta. Nat Nanotechnol 2011; 6:263-4; PMID:21546898; http://dx.doi.org/10.1038/nnano.2011.65
- Myllynen PK, Loughran MJ, Howard CV, Sormunen R, Walsh AA, Vähäkangas KH. Kinetics of gold nanoparticles in the human placenta. Reprod Toxicol 2008; 26:130-7; PMID:18638543; http://dx.doi.org/10.1016/j.reprotox.2008.06.008
- Yamashita K, Yoshioka Y, Higashisaka K, Mimura K, Morishita Y, Nozaki M, Yoshida T, Ogura T, Nabeshi H, Nagano K, et al. Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. Nat Nanotechnol 2011; 6:321-8; PMID:21460826; http://dx.doi.org/10.1038/nnano.2011.41
- Nanoparticles Impact Pregnancy in Mice. Chem Eng News 2011; 89:35
- Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 2012; 161:264-73; PMID:21872624; http://dx.doi.org/10.1016/j.jconrel.2011.08.017
- Qiao R, Jia Q, Hüwel S, Xia R, Liu T, Gao F, Galla HJ, Gao M. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier. ACS Nano 2012; 6:3304-10; PMID:22443607; http://dx.doi.org/10.1021/nn300240p
- Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. J Control Release 2011; 154:103-7; PMID:21616104; http://dx.doi.org/10.1016/j.jconrel.2011.05.010
- Malhotra M, Prakash S. Targeted Drug Delivery Across Blood-Brain-Barrier Using Cell Penetrating Peptides Tagged Nanoparticles. Curr Nanosci 2011; 7:81-93; http://dx.doi.org/10.2174/157341311794480336
- Gan CW, Feng SS. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 2010; 31:7748-57; PMID:20673685; http://dx.doi.org/10.1016/j.biomaterials.2010.06.053
- Park K. Transport across the blood-brain barrier using albumin nanoparticles. J Control Release 2009; 137:1; PMID:19427883; http://dx.doi.org/10.1016/j.jconrel.2009.05.004
- Garcia GJM, Kimbell JS. Deposition of inhaled nanoparticles in the rat nasal passages: dose to the olfactory region. Inhal Toxicol 2009; 21:1165-75; PMID:19831956; http://dx.doi.org/10.3109/08958370902882713
- Aschner M. Chapter 8 - Nanoparticles: Transport across the olfactory epithelium and application to the assessment of brain function in health and disease. Prog Brain Res 2009; 180:141-52; PMID:20302833; http://dx.doi.org/10.1016/S0079-6123(08)80008-8
- Wick P, Malek A, Manser P, Meili D, Maeder-Althaus X, Diener L, Diener PA, Zisch A, Krug HF, von Mandach U. Barrier capacity of human placenta for nanosized materials. Environ Health Perspect 2010; 118:432-6; PMID:20064770; http://dx.doi.org/10.1289/ehp.0901200
- Takeda K, Suzuki KI, Ishihara A, Kubo-Irie M, Fujimoto R, Tabata M, Oshio S, Nihei Y, Ihara T, Sugamata M. Nanoparticles Transferred from Pregnant Mice to Their Offspring Can Damage the Genital and Cranial Nerve Systems. J Health Sci 2009; 55:95-102; http://dx.doi.org/10.1248/jhs.55.95
- Yang H, Sun C, Fan Z, Tian X, Yan L, Du L, Liu Y, Chen C, Liang XJ, Anderson GJ, et al. Effects of gestational age and surface modification on materno-fetal transfer of nanoparticles in murine pregnancy. Sci Rep 2012; 2:847; PMID:23150793; http://dx.doi.org/10.1038/srep00847
- Chithrani BD, Chan WC. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 2007; 7:1542-50; PMID:17465586; http://dx.doi.org/10.1021/nl070363y
- Leroueil PR, Berry SA, Duthie K, Han G, Rotello VM, McNerny DQ, Baker JR Jr., Orr BG, Holl MM. Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers. Nano Lett 2008; 8:420-4; PMID:18217783; http://dx.doi.org/10.1021/nl0722929
- Machy P, Serre K, Leserman L. Class I-restricted presentation of exogenous antigen acquired by Fcgamma receptor-mediated endocytosis is regulated in dendritic cells. Eur J Immunol 2000; 30:848-57; PMID:10741401; http://dx.doi.org/10.1002/1521-4141(200003)30:3<848::AID-IMMU848>3.0.CO;2-Q